SKSerena Patricia Koenig

Serena Patricia Koenig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Serena Patricia Koenig has a total of 343 co-authors. Here are the top co-authors by number of shared publications:

  • Patrice Severe

    19 shared publications
  • Alexandra Apollon

    Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) , Port-au-Prince

    11 shared publications
  • Jean W. Pape

    Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic Infections (GHESKIO)

    10 shared publications
  • Jean William Pape

    Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) Port‐au‐Prince Haiti

    10 shared publications
  • Patrice Joseph

    Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) , Port-au-Prince

    10 shared publications
  • Vanessa Rouzier

    Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic Infections (GHESKIO)

    10 shared publications

Latest Publications

  • Open Access

    High Burden of Cardiovascular Disease and Mental Health Illness Comorbidity in Urban Haiti

    by Lily D. Yan, Miranda Metz, Rodney Sufra, Reichling St Sauveur, Kelly Celestin, Erline Hilaire, Suzanne Edwidge Marcellin, Sarine Auguste, Anju Ogyu, Catherine Bennett, et al.

    Background: People living in low‐income settings facing humanitarian crises are at risk for comorbid cardiovascular disease ( CVD ) and mental health ( MH ) illness, yet there are limited population‐based data available. Methods: We estimated CVD – MH illness comorbidity and associated risk factors using enrollment data from the Haiti Cardiovascular Disease Cohort Study (2019–2021). Adults aged >18 years were recruited using multistage random sampling across Port‐au‐Prince. Prevalent CVD (hypertension, heart failure, stroke, or myocardial infarction) was adjudicated by a physician panel integrating clinical examinations, imaging, and laboratory data. Prevalent MH illness was defined as depression symptoms (Patient Health Questionnaire 9 score >5) or stress (Perceived Stress Score >5). We conducted multivariable Poisson regression to analyze the association between risk factors (age, sex, low income, education, smoking, alcohol consumption) and the outcome of prevalent CVD – MH illness . Results: Among 2993 adults in this analysis, the median age was 40 years, 42% were women, and 70% earned an income <1 USD per day. CVD – MH illness comorbidity prevalence was 30% (95% CI , 28–32), with CVD prevalence 34% and MH 85%. In multivariable regression, older age (≥60 versus <40 years; adjusted prevalence ratio, 5.79 [95% CI , 4.57–7.38]), female sex (female versus male sex: adjusted prevalence ratio, 1.22 [95% CI , 1.06–1.42]), and lower education (secondary versus primary education: adjusted prevalence ratio, 1.46 [95% CI , 1.24–1.71]) were significantly associated with CVD – MH illness after adjusting for all other factors. Conclusions: CVD – MH illness comorbidity is highly prevalent in urban Haiti, especially among older adults and women. These findings underscore the need for integrated, contextually adapted approaches to address multimorbidity in crisis‐affected low‐ and middle‐income countries .

  • Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study

    by Jean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, Cissy Kityo, Michael D Hughes, Catherine Godfrey, N Sarita Shah, Urvi M Parikh, Gary Maartens, Francis Kanyike, et al.


  • Open Access

    Three-Year Outcomes After Programmatic Transitioning to Dolutegravir in the Context of Severe Civil Unrest in Haiti

    by Bernard Liautaud, Ana Sanchez Chico, Youry Macius, Sosina Abuhay, Patrice Joseph, Harrison T Reeder, Theo Bolas, Adias Marcelin, Colette Guiteau Moïse, Alexandra Apollon, et al.

    Background: Tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) is widely prescribed in low and middle-income countries. Data on long-term outcomes are limited. Methods: We included all persons with HIV (PWH) ≥15 years of age who initiated or switched to TLD in Port-au-Prince, Haiti. We described treatment outcomes by pre-switch viral load and assessed predictors of virologic failure using multivariable logistic regression. Results: A total of 10 354 PWH initiated or switched to TLD from November 2018 to March 2021, and were included in the analyses. Of these, 2217 (21.4%) were ART-naïve and 8137 (78.6%) switched from an non-nucleoside reverse transcriptase inhibitor (NNTRI)-based regimen. Median follow-up time on TLD was 2.8 years (IQR: 2.3, 3.1). HIV-1 RNA <1000 copies/mL was achieved at the latest measurement in 92.7% of recipients of care (RoC) with pre-switch suppression, 88.5% without pre-switch viral load, 58.3% with pre-switch failure, and 81.8% of RoC ART-naïve at TLD initiation. Among treatment-experienced RoC, predictors of ≥1000 copies/mL at latest test included younger age (adjusted odds ratio [aOR]: 0.44; 95% CI: 0.34, 0.57 for age ≥50 vs <30 years), shorter time on ART (aOR: 0.91; 95% CI: 0.89, 0.93/year), lower education (aOR: 1.31; 95% CI: 1.13, 1.52), and higher pre-switch viral load: (aOR: 7.23; 95% CI: 6.06, 8.63 for ≥10 000 vs < 1000 copies/mL). Conclusions: Virologic outcomes on TLD are outstanding for PWH with pre-switch suppression. However, rates of virologic suppression are suboptimal among PWH who were ART-naïve at TLD initiation, and among those with a history of pre-switch failure, additional interventions are necessary, including access to long-acting treatment regimens.


  • Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial

    by Patrice Severe, Samuel Pierre, Fabienne Homeus, Jean Bernard Marc, Letizia Trevisi, Maria Linda Aristhomene, Guirlaine R Bernadin, Kerlyne Lavoile, Vanessa Rivera, Carl Frederic Duchatellier, et al.


  • Open Access

    Temporal trends in tuberculosis and time from enrolment in care to antiretroviral therapy initiation: A multicountry cohort study from Latin America

    by Bryan E Shepherd, Zhuohui Liang, Ahra Kim, Carina Cesar, Valdilea G. Veloso, Claudia P. Cortes, Marco T. Luque, Brenda Crabtree-Ramirez, Eduardo Gotuzzo, Karu Jayathilake, et al.


  • Open Access

    Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites

    by Cissy Kityo, Caitlyn McCarthy, Serena P Koenig, Michael D Hughes, Carole L Wallis, Isaac Tsikhutsu, Cornelius Munyanga, Noluthando Mwelase, Marije Van Schalkwyk, Jean Bernard Marc, et al.

    Background: Tenofovir/lamivudine/dolutegravir (TLD) is widely prescribed worldwide. We report virologic and resistance outcomes for patients initiating or switching to TLD. Methods: A prospective observational study was performed at 13 AIDS Clinical Trials Group sites in 6 President's Emergency Plan for AIDS Relief-supported countries coincident with TLD rollout. This report includes results from 2 groups: group 1 (Gp1) were virally suppressed on nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy (ART) and group 2 (Gp2) were ART-naïve at TLD initiation. The primary objective was to estimate the proportions of participants with HIV-1 RNA ≤1000 copies/mL and frequency of dolutegravir resistance mutations 6 months after TLD initiation. Results: From October 2019 through July 2022, we enrolled 425 participants in Gp1 and 179 in Gp2. Two in Gp1 (0.5%) and 3 in Gp2 (1.7%) discontinued TLD by 6 months due to adverse events considered related to TLD (n = 4) and participant decision (n = 1). Ninety-three percent of participants in Gp1 and 92% in Gp2 who were still on TLD had a 6-month plasma HIV-1 RNA. Plasma HIV-1 RNA ≤1000, ≤ 200, and <50 copies/mL was achieved in 99%, 98%, and 96% in Gp1 and in 90%, 87%, and 85% in Gp2, respectively. A new integrase mutation (T97A/T) was observed in 1 participant in Gp1 and none in Gp2. Conclusions: TLD was well tolerated and achieved or maintained viral suppression (≤1000 copies/mL) in 90% of ART-naïve and 99% of participants with preswitch viral suppression. An emerging integrase strand transfer inhibitor mutation of uncertain significance was detected in only 1 participant. These data support early tolerability, virologic efficacy, and rare integrase strand transfer inhibitor resistance emergence with TLD transition or initiation in programmatic settings.


  • Open Access

    Early initiation of fast‐track care for persons living with HIV initiating dolutegravir‐based regimens during a period of severe civil unrest in Port‐au‐Prince, Haiti: a pilot randomized trial

    by Jean Bernard Marc, Samuel Pierre, Othnia Ducatel, Fabienne Homeus, Abigail Zion, Vanessa R. Rivera, Nancy Dorvil, Patrice Severe, Colette Guiteau, Vanessa Rouzier, et al.

    Introduction: Differentiated service delivery (DSD) models have been widely implemented for patients in stable HIV care. However, DSD has rarely been offered to newly diagnosed patients. We assessed the effectiveness of early fast‐track care during a period of severe civil unrest in Port‐au‐Prince, Haiti. Methods: We conducted a pilot randomized trial among adults presenting with early HIV disease to determine whether early fast‐track care (8−12 weeks after same‐day HIV testing and antiretroviral therapy [ART] initiation) was associated with superior outcomes compared with standard (deferred eligibility for fast‐track care). All participants received tenofovir/lamivudine/dolutegravir (TLD), and HIV‐1 RNA n = 116) and early fast‐track ( n = 129) groups. All initiated TLD on the day of HIV diagnosis. In the early fast‐track group, one (0.8%) died, 12 (9.3%) were internally displaced/emigrated, five (3.9%) were lost‐to‐follow‐up (LTFU), two (1.6%) had a gap in care/later return, one (0.8%) was transferred and 108 (83.7%) were retained; 88 (68.2%) received 48‐week viral load testing and 80 (90.9% of tested; 62.0% of randomized) had HIV‐1 RNA <200 copies/ml. In the standard group, two (1.7%) died, six (5.2%) were internally displaced/emigrated, three (2.6%) were LTFU, one (0.9%) had a gap in care/later return, one (0.9%) was transferred and 103 (88.8%) were retained; 78 (67.2%) received 48‐week viral load testing and 66 (84.6% of tested; 56.9% of randomized) had HIV‐1 RNA <200 copies/ml. By design, the sample size of this pilot study was too small to provide definitive evidence of treatment effect, but the primary outcome was numerically higher in the early fast‐track group (62.0% vs. 56.9%; RD: 0.051: 95% CI: −0.072, 0.174). Conclusions: Early fast‐track care was associated with high levels of viral suppression among adults initiating same‐day TLD, despite severe civil unrest in Haiti. Completion of 48‐week viral load testing was suboptimal, due to the need for participants to leave Port‐au‐Prince during peak periods of gang‐related violence, and the lack of availability of viral load testing for those receiving non‐facility‐based ART.


  • Open Access

    Predictors of Clinical Outcomes Among People With Human Immunodeficiency Virus and Tuberculosis Symptoms After Rapid Treatment Initiation in Haiti

    by Aaron Richterman, Nancy Dorvil, Vanessa Rivera, Heejung Bang, Patrice Severe, Kerylyne Lavoile, Samuel Pierre, Alexandra Apollon, Emelyne Dumond, Guyrlaine Pierre Louis Forestal, et al.

    Background: Few studies have evaluated baseline predictors of clinical outcomes among people with human immunodeficiency virus (HIV) starting antiretroviral therapy (ART) in the modern era of rapid ART initiation. Methods: We conducted a secondary analysis of a previously reported open-label randomized controlled trial of 2 rapid treatment initiation strategies for people with treatment-naive HIV and tuberculosis symptoms at a large urban clinic in Haiti. We used logistic regression models to assess associations between baseline characteristics and (1) retention in care at 48 weeks, (2) HIV viral load suppression at 48 weeks (among participants who underwent viral load testing), and (3) all-cause mortality. For the viral load suppression outcome, we used inverse probability weighting to account for potential selection bias resulting from exclusion of participants who did not undergo viral load testing. Results: A total of 500 participants were enrolled in the study from November 2017 to January 2020. Tuberculosis was diagnosed in 88 participants (18%), and ART was started in 494 (99%). After multivariable adjustment, less than secondary school education (adjusted odds ratio [AOR] 0.21 [95% confidence interval (CI), .10–.46]) was significantly associated with a reduced odds of retention in care. Dolutegravir initiation (AOR, 2.57 [95% CI, 1.22–5.43]), age (1.42 per 10-year increase [1.01–1.99]), and tuberculosis diagnosis (3.92 [1.36–11.28]) were significantly associated with increased odds of retention. Age (AOR, 1.36 [95% CI, 1.05–1.75]) and dolutegravir initiation (1.75 [1.07–2.85]) were positively associated with viral suppression, and tuberculosis diagnosis (0.50 [.28–.89) was negatively associated with viral suppression, with similar findings after incorporation of inverse probability weights. Higher CD4 cell count at enrollment was significantly associated with a lower odds of mortality (unadjusted odds ratio, 0.69 [95% CI, .55–.87]), and anemia was associated with a significantly greater odds of mortality (4.86 [1.71–13.81]). Conclusions: We identified sociodemographic, treatment-related, clinical, and laboratory-based predictors of clinical outcomes. These characteristics may serve as markers of subpopulations that could benefit from additional interventions to support treatment success after rapid treatment initiation.


  • Open Access

    Early Initiation of Fast-Track Care for Persons Living with HIV Initiating Dolutegravir-Based Regimens during a Period of Severe Civil Unrest in Port-au-Prince, Haiti

    by Jean Bernard Marc, Samuel Pierre, Othnia Ducatel, Fabienne Homeus, Abigail Zion, Vanessa R. Rivera, Nancy Dorvil, Patrice Severe, Colette Guiteau, Vanessa Rouzier, et al.

    Introduction Differentiated service delivery (DSD) models have been widely implemented for patients who are established in HIV care. However, DSD has rarely been offered to those newly diagnosed with HIV. We conducted a study to assess the effectiveness of early fast-track care during the COVID-19 pandemic and a period of severe civil unrest at GHESKIO, in Haiti. Methods We conducted a pilot randomized trial among adults presenting with World Health Organization Stage 1 or 2 disease at HIV diagnosis to determine whether early fast-track care (at eight to 12 weeks after same-day HIV testing and ART initiation) was associated with superior outcomes, compared with standard care (deferred eligibility for fast-track care). All participants received tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD), and HIV-1 RNA Results From December 13, 2020, to August 19, 2022, 247 participants were randomized; 2 met protocol-specified criteria for late exclusions, leaving a study population of 245 (standard: 116; early fast-track: 129). All participants initiated TLD on the day of HIV diagnosis. In the standard group, 2 (1.7%) died, 106 (91.4%) were retained in care, and 78 (67.2%) received 48-week viral load testing; 66 (84.6% of those tested; 56.9% of those randomized) had HIV-1 RNA Conclusions The provision of fast-track care as early as 8 weeks after TLD initiation is associated with high levels of retention in care and viral suppression in a setting of severe civil unrest, with no difference in outcome compared to deferred eligibility for fast-track care. Completion of 48-week viral load testing was suboptimal; low-cost point-of-care testing capacity may facilitate completion of viral load testing in this setting.

  • Open Access

    Potential Utility of C-reactive Protein for Tuberculosis Risk Stratification Among Patients With Non-Meningitic Symptoms at HIV Diagnosis in Low- and Middle-income Countries

    by Kathryn Dupnik, Vanessa R Rivera, Nancy Dorvil, Yanique Duffus, Hanane Akbarnejad, Yipeng Gao, Jingyi Liu, Alexandra Apollon, Emelyne Dumont, Cynthia Riviere, et al.

    Background: The World Health Organization recommends initiating same-day antiretroviral therapy (ART) while tuberculosis (TB) testing is under way for patients with non-meningitic symptoms at HIV diagnosis, though safety data are limited. C-reactive protein (CRP) testing may improve TB risk stratification in this population. Methods: In this baseline analysis of 498 adults (>18 years) with TB symptoms at HIV diagnosis who were enrolled in a trial of rapid ART initiation in Haiti, we describe test characteristics of varying CRP thresholds in the diagnosis of TB. We also assessed predictors of high CRP as a continuous variable using generalized linear models. Results: Eighty-seven (17.5%) participants were diagnosed with baseline TB. The median CRP was 33.0 mg/L (interquartile range: 5.1, 85.5) in those with TB, and 2.6 mg/L (interquartile range: 0.8, 11.7) in those without TB. As the CRP threshold increased from ≥1 mg/L to ≥10 mg/L, the positive predictive value for TB increased from 22.4% to 35.4% and negative predictive value decreased from 96.9% to 92.3%. With CRP thresholds varying from <1 to <10 mg/L, a range from 25.5% to 64.9% of the cohort would have been eligible for same-day ART and 0.8% to 5.0% would have untreated TB at ART initiation. Conclusions: CRP concentrations can be used to improve TB risk stratification, facilitating same-day decisions about ART initiation. Depending on the CRP threshold, one-quarter to two-thirds of patients could be eligible for same-day ART, with a reduction of 3- to 20-fold in the proportion with untreated TB, compared with a strategy of same-day ART while awaiting TB test results.